Non-Small Cell Lung Cancer Coverage from Every Angle

Brigatinib in Crizotinib-Refractory ALK-Positive Non–Small Cell Lung Cancer

By: Meg Barbor, MPH
Posted: Friday, July 28, 2017

The ALK inhibitor brigatinib showed activity, “robust” progression-free survival, and acceptable safety in patients with ALK-positive non–small cell lung cancer who had been previously treated with crizotinib, according to updated data from the randomized phase II ALTA trial published by Myung-Ju Ahn, MD, of Samsung Hospital, Seoul, South Korea, and colleagues, in the Journal of Clinical Oncology.

A total of 222 patients with crizotinib-refractory advanced ALK-positive NSCLC were stratified by the presence of brain metastases and best response to prior crizotinib. They were randomized 1:1 to receive brigatinib at 90 mg/day in arm A (n=112) or 180 mg/day with a 7-day lead-in at 90 mg in arm B (n=110).

As of May 31, 2016, the objective response rate was 45% in arm A and 55% in arm B. Median progression-free survival was 8.8 months in arm A and 15.6 months in arm B. In patients with measurable baseline brain metastases (A/B, n=26/n=18), confirmed intracranial objective response rate was 46% and 67% in arms A and B, respectively.

Brigatinib demonstrated efficacy in both arms of the study, but the 180-mg dose with the 90 mg lead-in was associated with an improvement in efficacy endpoints with no increase in early pulmonary adverse events, the investigators reported.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.